Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1

Conditions

Pancreatic Neoplasms 33Breast Neoplasms 27Carcinoma, Non-Small-Cell Lung 22Triple Negative Breast Neoplasms 19Ovarian Neoplasms 18Lung Neoplasms 18Fallopian Tube Neoplasms 17Neoplasm Metastasis 15Squamous Cell Carcinoma of Head and Neck 12Endometrial Neoplasms 10Neoplasms 9Oropharyngeal Neoplasms 6Mouth Neoplasms 6Esophageal Neoplasms 6Cholangiocarcinoma 6Melanoma 5Colorectal Neoplasms 5Carcinoma 5Adenocarcinoma Of Esophagus 5Stomach Neoplasms 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4Carcinoma, Transitional Cell 4Anatomic Stage I Breast Cancer AJCC v8 4Pancreatic Adenocarcinoma 3Inflammatory Breast Neoplasms 3Head and Neck Neoplasms 3Gallbladder Neoplasms 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Squamous Cell 3

Interventions

Oxaliplatin 19pembrolizumab 13Fluorouracil 12Leucovorin 11Capecitabine 11Paclitaxel 10Gemcitabine 8Docetaxel 8zolbetuximab 6cemiplimab 6Cisplatin 6Albumin-Bound Paclitaxel 6durvalumab 5Ramucirumab 5Radiotherapy 5Irinotecan 4Cyclophosphamide 4130-nm albumin-bound paclitaxel 4trastuzumab deruxtecan 3tislelizumab 3lenvatinib 3enzalutamide 3darolutamide 3Trastuzumab 3Taxes 3S 1 (combination) 3Radiosurgery 3Pemetrexed 3Nivolumab 3Carboplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Adenocarcinoma × Taxes × 1 year × Clear all
NCT03415854 2026-05-12

NABPLAGEMD

HonorHealth Research Institute

Phase 2 Completed
34 enrolled 11 charts
Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT06561685 2026-04-20

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Eli Lilly and Company

Phase 1 Recruiting
340 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Neoplasm Metastasis

NCT04543071 2025-06-19

Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

Columbia University

Phase 2 Recruiting
10 enrolled
Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡